Biogen (BIIB) Financial Analysis & Valuation | Quarter Chart
Biogen (BIIB)
BIIBPrice: $216.63
Fair Value: 🔒
🔒score
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaq... more
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and ... more
Description
Shares
| Market Cap | $31.98B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - General |
| Country | US | CEO | Christopher A. Viehbacher |
| IPO Date | 1991-09-17 | CAGR | 0.18% |
| Employees | 7,605 | Website | www.biogen.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
BIIB chart loading...
Fundamentals
Technicals
| Enterprise Value | $33.54B | P/E Ratio | 13.68 |
| Forward P/E | 12.15 | PEG Ratio | 0.7 |
| P/S Ratio | 3.62 | P/B Ratio | 1.91 |
| P/CF Ratio | 13.76 | P/FCF Ratio | 13.64 |
| EPS | $15.84 | EPS Growth 1Y | -7.8% |
| EPS Growth 3Y | -56.64% | EPS Growth 5Y | -51% |
| Revenue Growth 1Y | 0.42% | Gross Margin | 0.7% |
| Operating Margin | 0.16% | Profit Margin | 0.14% |
| ROE | 0.08% | ROA | 0.05% |
| ROCE | 0.06% | Current Ratio | 3.06 |
| Quick Ratio | 2.41 | Cash Ratio | 1.13 |
| Debt/Equity | 0.35 | Interest Coverage | 5.61 |
| Altman Z Score | 3.56 | Piotroski Score | 5 |